Insider Selling: Privia Health Group (NASDAQ:PRVA) Director Sells 7,788 Shares of Stock

Privia Health Group, Inc. (NASDAQ:PRVA) Director Matthew Shawn Morris sold 7,788 shares of Privia Health Group stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $24.99, for a total transaction of $194,622.12. Following the completion of the sale, the director directly owned 68,188 shares of the company’s stock, valued at approximately $1,704,018.12. The trade was a 10.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Matthew Shawn Morris also recently made the following trade(s):

• On Friday, February 27th, Matthew Shawn Morris sold 16,550 shares of Privia Health Group stock. The shares were sold at an average price of $25.00, for a total value of $413,750.00.
• On Friday, December 12th, Matthew Shawn Morris sold 13,647 shares of Privia Health Group stock. The stock was sold at an average price of $25.01, for a total value of $341,311.47.

Privia Health Group Stock Performance

Shares of NASDAQ PRVA traded up $0.29 during mid-day trading on Monday, reaching $24.04. 1,472,614 shares of the company traded hands, compared to its average volume of 813,700. The stock has a market cap of $2.96 billion, a PE ratio of 141.41, a price-to-earnings-growth ratio of 1.59 and a beta of 0.82. The company’s fifty day moving average is $23.07 and its two-hundred day moving average is $23.50. Privia Health Group, Inc. has a fifty-two week low of $18.77 and a fifty-two week high of $26.51.

Privia Health Group (NASDAQ:PRVA) last posted its earnings results on Thursday, February 26th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.04 by $0.21. The firm had revenue of $541.17 million during the quarter, compared to analyst estimates of $516.61 million. Privia Health Group had a return on equity of 3.06% and a net margin of 1.08%.The company’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.21 EPS. Research analysts forecast that Privia Health Group, Inc. will post 0.14 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Stephens reiterated an “overweight” rating and issued a $32.00 target price on shares of Privia Health Group in a research note on Thursday, December 4th. Wolfe Research set a $31.00 target price on shares of Privia Health Group in a research report on Tuesday, January 6th. Truist Financial raised their price target on Privia Health Group from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Monday. Citigroup reiterated a “market outperform” rating on shares of Privia Health Group in a research note on Tuesday, January 6th. Finally, BMO Capital Markets initiated coverage on Privia Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $30.00 price objective for the company. Thirteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $30.93.

Hedge Funds Weigh In On Privia Health Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in shares of Privia Health Group by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 12,098,933 shares of the company’s stock worth $301,263,000 after acquiring an additional 607,447 shares during the period. Durable Capital Partners LP increased its position in shares of Privia Health Group by 1.8% during the third quarter. Durable Capital Partners LP now owns 11,691,685 shares of the company’s stock valued at $291,123,000 after purchasing an additional 203,842 shares during the period. State Street Corp raised its stake in shares of Privia Health Group by 1.5% in the second quarter. State Street Corp now owns 4,171,069 shares of the company’s stock valued at $95,935,000 after purchasing an additional 61,853 shares in the last quarter. Van Berkom & Associates Inc. raised its stake in shares of Privia Health Group by 1.8% in the fourth quarter. Van Berkom & Associates Inc. now owns 3,844,256 shares of the company’s stock valued at $91,147,000 after purchasing an additional 69,691 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Privia Health Group by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 2,814,290 shares of the company’s stock worth $66,738,000 after purchasing an additional 31,204 shares during the period. 94.48% of the stock is currently owned by institutional investors.

Privia Health Group Company Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.